Literature DB >> 18775109

ONTARGET Study of Telmisartan, Ramipril, or Both in High-Risk Patients.

C Venkata S Ram.   

Abstract

Entities:  

Year:  2008        PMID： 18775109     DOI： 10.1007/s11906-008-0065-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  20 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 4.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.

Authors:  Gilles R Dagenais; Janice Pogue; Kim Fox; Marteen L Simoons; Salim Yusuf
Journal:  Lancet       Date:  2006-08-12       Impact factor: 79.321

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.

Authors:  Philip Jong; Salim Yusuf; Michel F Rousseau; Sylvie A Ahn; Shrikant I Bangdiwala
Journal:  Lancet       Date:  2003-05-31       Impact factor: 79.321

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors:  Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749
View more
  1 in total

1.  Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production.

Authors:  Juliano R Guerreiro; Claudiana Lameu; Eduardo F Oliveira; Clécio F Klitzke; Robson L Melo; Edlaine Linares; Ohara Augusto; Jay W Fox; Ivo Lebrun; Solange M T Serrano; Antonio C M Camargo
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.